Group 1: IVD Industry Insights - The IVD industry in China is currently under short-term pressure, with leading companies actively expanding overseas [4][6] - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [4] - The Chinese immunodiagnostics market is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [5] Group 2: Health元 Company Overview - Health元, a large comprehensive pharmaceutical group, is focusing on innovation and internationalization to drive growth [7] - The company is expected to achieve revenues of RMB 15.81 billion, RMB 17.02 billion, and RMB 18.27 billion from 2025 to 2027, with respective growth rates of 1.2%, 7.6%, and 7.4% [8] - The core products of Health元 are expected to see reduced pricing pressure, with new products like tobramycin inhalation solution and maropitant capsules set to contribute to revenue growth [7][8]